autologous umbilical cord blood

Autologous umbilical cord blood is a cell therapy product derived from a patient's own umbilical cord blood, which is collected at birth and cryopreserved for potential future use. The therapy utilizes the diverse mixture of stem and progenitor cells, including hematopoietic stem cells and mononuclear cells, to promote tissue repair and modulate inflammatory responses. In the context of pediatric neurological disorders like cerebral palsy and hypoxic-ischemic encephalopathy, the cells are believed to act via paracrine signaling, releasing neurotrophic factors and cytokines that facilitate neural connectivity, reduce neuroinflammation, and support endogenous brain repair. Clinical trials, particularly those led by Duke University, have indicated that intravenous infusion of these cells is safe and can lead to significant improvements in motor function and brain structural connectivity when administered at a sufficient dose (typically ≥2 x 10⁷ cells/kg). It has also been investigated for its potential to preserve beta-cell function in Type 1 diabetes and to ameliorate neural and cardiac injury in neonates with congenital heart defects.

Other names

autologous UCBautologous cord bloodautologous umbilical cord blood reinfusionautologous cord blood mononuclear cells